- Home
- DAWN vs NCLH Comparison
DAWN vs NCLH Comparison
Compare DAWN & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- NCLH
- Stock Information
- Founded
- DAWN 2018
- NCLH 1966
- Country
- DAWN United States
- NCLH United States
- Employees
- DAWN N/A
- NCLH N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- NCLH Marine Transportation
- Sector
- DAWN Health Care
- NCLH Consumer Discretionary
- Exchange
- DAWN Nasdaq
- NCLH Nasdaq
- Market Cap
- DAWN 1.3B
- NCLH 12.1B
- IPO Year
- DAWN 2021
- NCLH 2013
- Fundamental
- Price
- DAWN $12.79
- NCLH $26.92
- Analyst Decision
- DAWN Strong Buy
- NCLH Buy
- Analyst Count
- DAWN 7
- NCLH 16
- Target Price
- DAWN $36.17
- NCLH $29.27
- AVG Volume (30 Days)
- DAWN 1.0M
- NCLH 9.5M
- Earning Date
- DAWN 10-30-2024
- NCLH 10-31-2024
- Dividend Yield
- DAWN N/A
- NCLH N/A
- EPS Growth
- DAWN N/A
- NCLH N/A
- EPS
- DAWN N/A
- NCLH 1.25
- Revenue
- DAWN $101,953,000.00
- NCLH $9,356,741,000.00
- Revenue This Year
- DAWN N/A
- NCLH $13.10
- Revenue Next Year
- DAWN $36.10
- NCLH $8.05
- P/E Ratio
- DAWN N/A
- NCLH $21.52
- Revenue Growth
- DAWN N/A
- NCLH 15.76
- 52 Week Low
- DAWN $11.94
- NCLH $14.69
- 52 Week High
- DAWN $18.07
- NCLH $28.64
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- NCLH 53.50
- Support Level
- DAWN $12.26
- NCLH $24.89
- Resistance Level
- DAWN $12.81
- NCLH $26.90
- Average True Range (ATR)
- DAWN 0.52
- NCLH 1.04
- MACD
- DAWN -0.05
- NCLH -0.23
- Stochastic Oscillator
- DAWN 28.94
- NCLH 56.86
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.